8-K: Certara Corrects Q2 2026 Earnings Call Misstatement

Certara, Inc. clarifies a misstatement regarding the 2025 adjusted EBITDA of its divested Regulatory and Medical Writing business, confirming no impact on prior financial results or future outlook.

Summary

• Certara, Inc. issued a clarification regarding a misstatement made during its second quarter 2026 earnings conference call on August 4, 2026.
• The misstatement concerned the 2025 adjusted EBITDA of the divested Regulatory and Medical Writing business.
• The spoken reference incorrectly stated approximately $17 million of adjusted EBITDA excluding unallocated overhead costs.
• The correct figure for 2025 adjusted EBITDA, including unallocated overhead costs, was approximately $17 million.
• The 2025 adjusted EBITDA generated by the Regulatory and Medical Writing business, excluding unallocated corporate expense that will remain with Certara, is approximately $23 million.
• An updated earnings presentation reflecting this correction has been posted on the company's website.
• This clarification has no impact on previously reported financial results, year-over-year comparisons, or the company's 2026 Financial Outlook.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it corrects a prior misstatement without impacting overall financial results or future outlook.

Positives

• The company has proactively corrected a misstatement, demonstrating transparency.
• The clarification confirms that previously reported financial results and year-over-year comparisons remain unaffected.
• The company's 2026 Financial Outlook is also confirmed to be unchanged by this correction.

Negatives

• A misstatement was made during a public earnings call and in the associated presentation, which could raise minor concerns about internal review processes.

Future Outlook

The company's 2026 Financial Outlook remains unchanged by this clarification.

Industry Context

StockSavvy.ai notes that corrections to financial reporting, while not ideal, are a standard part of the disclosure process. The key takeaway here is the confirmation that the core business and future projections are not impacted, which is typical for adjustments related to divested segments.

Stakeholder Impact

• Shareholders: Minimal impact as previously reported financials and future outlook remain unchanged.
• Investors: Increased confidence in the company's transparency and accuracy in reporting, despite the initial misstatement.

Next Steps

• The company has updated its second quarter 2026 earnings presentation on its website.

Key Dates

Keywords

EBITDA, Earnings Call, Financial Presentation, Regulatory Business, Medical Writing, Divested Business, Corporate Expense, Financial Outlook